Evaluation of Hidden Hearing Loss and Vestibular Damage Induced by Anti-cancer Treatments

Status: Recruiting
Location: See location...
Intervention Type: Diagnostic test
Study Type: Observational
SUMMARY

• Visit the clinic once every 2 weeks for checkups and tests The goal of this clinical trial is to learn if systematic hearing tests (eg fonctional assesment, electrophysiology and seric biomarkers) can diagnose hidden hearing loss or vestibular troubles in a population of patients treated for cancer; population study will include different population in terms of sex/gender, age, medical condition (cancer patients treated with surgery alone and/or radiotherapy and/or chemotherapy, and healthy volunteers). The main question it aims to answer is: • To assess the ototoxicity of anticancer drugs using a combination of auditory functional tests (including speech audiometry in noise), vestibular test , plasmatic samples and electrophysiological measures. Participants will be studied: Either only after exposition (single visit) Or before, during and after the exposition to potential otototoxic agents with a 4 times Visit the clinic checkups and tests (one before, two while ongoing potential ototoxic agents and 1 post exposition) Participants will complete questionnaires, undergo audiometric and electrophysiological tests, and their routine biomedical data will be studied, without any modification of the routine care (planned cancer treatment)

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: t
View:

• Age 18 and over

• Registered with social security

• Signed consents

• Absence of presbycusis prior to cancer treatment (groups A and C)

• No known presbycusis (group B)

• Previous exposure to an ototoxic/neurotoxic agent (group A)

• Indication for initiation of ototoxic/neurotoxic therapy (group C)

Locations
Other Locations
France
HIA Bégin
RECRUITING
Paris
Contact Information
Primary
François-Régis FERRAND
francois-regis.ferrand@def.gouv.fr
0178651249
Time Frame
Start Date: 2024-06-19
Estimated Completion Date: 2027-09-19
Participants
Target number of participants: 540
Treatments
A:Previously exposed to CISPLATIN with significant ATL damage
Groupe A
A:Previously exposed to CISPLATIN without significant ATL damage
Groupe A
A:Previously exposed to cochlear RADIOTHERAPY with significant ATL damage
Groupe A
A:Previously exposed to cochlear RADIOTHERAPY WITHOUT significant ATL damage
Groupe A
A:Previously exposed to cochlear RADIOTHERAPY & CISPLATIN with significant ATL damage
Groupe A
A:Previously exposed to cochlear RADIOTHERAPY & CISPLATIN WITHOUT significant ATL damage
Groupe A
A:Previously exposed to OXALIPLATIN
Groupe A
A:Previously exposed to CARBOPLATIN
Groupe A
A:Previously exposed to TAXANES
Groupe A
A:Previously exposed to VINCALCALOIDS
Groupe A
A:Previously exposed to other neurotoxicant
Groupe A
B:Patients cured of cancer without ototoxic or neurotoxic exposure
Groupe B
B:Companions without ototoxic or neurotoxic exposure
Groupe B
A:Hyperacusic patients following cancer treatment
Groupe A
A:Tinnitus patients following cancer treatment
Groupe A
A:Patients with vestibular disorders following cancer treatment
Groupe A
C:Patients with an indication for CISPLATIN recruited prior to any treatment
Groupe C
C:Patients indicated for cochlear radiotherapy and recruited prior to treatmen
Groupe C
C:Patients with indication for CISPLATIN and cochlear radiotherapy recruited prior any treatment
Groupe C
C:Patients with an indication for OXALIPLATIN treatment recruited prior to any treatment
Groupe C
C:Patients with indication for CARBOPLATIN recruited prior to any treatment
Groupe C
C:Patients with indication for TAXANES therapy recruited prior to any treatment
Groupe C
C:Patients with indication for VINCALCALOIDES or other neurotoxicant
Groupe C
Related Therapeutic Areas
Sponsors
Leads: Direction Centrale du Service de Santé des Armées

This content was sourced from clinicaltrials.gov